(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/165015 A1

(51) International Patent Classification:
A61K 31/5377 (2006.01) *A61P 35/00* (2006.01)
A61K 9/20 (2006.01)

(21) International Application Number:
PCT/EP2020/052971

(22) International Filing Date:
06 February 2020 (06.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
19156399.8 11 February 2019 (11.02.2019) EP

(71) Applicant: **BAYER AKTIENGESELLSCHAFT** [DE/DE]; Kaiser-Wilhelm-Allee 1, 51373 Leverkusen (DE).

(72) Inventors: **KRICKAU, Dennis**; Südwestkorso 26, 14197 Berlin (DE). **LAGKADINOU, Eleni**; Akazienallee 39, 14050 Berlin (DE). **WENGNER, Antje, Margret**; Binzstr. 60, 13189 Berlin (DE). **KRAUSE, Michael**; Tietzenweg 114, 12203 Berlin (DE). **SERNO, Peter**; Offenbachstr. 12, 51467 Bergisch Gladbach (DE). **BAIRLEIN, Michaela**; Hindenburgstr. 54b, 42117 Wuppertal (DE). **WILKINSON, Gary**; Gieselerstr. 25, 10713 Berlin (DE). **WATTERS, Siobhan**; Apartment 24, Park Royal 841D Lisburn Road, Belfast BT9 7GY (GB). **ASSI, Pardis**; 70 Lady Wallace road, Lisburn BT28 3WS (GB).

(74) Agent: **BIP PATENTS**; Alfred-Nobel-Str. 10, 40789 Monheim am Rhein NRW (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*

WO 2020/165015 A1

(54) **Title:** THE ATR KINASE INHIBITOR BAY1895344 FOR USE IN THE TREATMENT OF A HYPER-PROLIFERATIVE DISEASE

(57) **Abstract:** The present invention relates to the ATR kinase inhibitor, 2-[(3R)-3-methylmorpholin-4-yl]-4-(1- methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine, for use in the treatment of a hyper- proliferative disease, characterized in that it is administered in an amount of from 10 mg to 160 mg per day, particularly in an amount of 60 to 160 mg per day. The present invention also relates to a pharmaceutical composition comprising 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5- yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine in an amount of from 5 mg to 80 mg and at least one pharmaceutically acceptable excipient. The present invention also relates to a process for manufacturing said pharmaceutical composition.